에 대한 최신 뉴스 Biogen (NASDAQ:BIIB) 주식

Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Technicals

Tech

Trading Ideas

BIIB

MRNA

MSTR

NVDA

PLTR

SMCI

슈퍼 마이크로 컴퓨터(NASDAQ:SMCI)는 이번 주 나스닥 100 지수의 자리가 위태로운 상황에서 줄타기를 하고 있다. 매년 12월 이 지수가 라인업을 조정함에 따라 캘리포니아주 산호세에 본사를 둔 이 회사는 모더나(NASDAQ:MRNA) 및 바이오젠(NASDAQ:BIIB)과 같은 실적이 저조한 다른 주식들과 함께 잠재적인 제외 대상에 올라 있다.

나스닥 100의 외곽에서 줄타기를 하는 SMIC: xAI, 엔비디아가 궤도 안정화에 도움이 될까?

Asia

Earnings

Large Cap

Mid Cap

DCOM

DLTR

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PDD 홀딩스(NASDAQ:PDD)의 주식은 상당한 상승 기회를 제시하고 있으며, 분석가들은 현재 수준에서 잠재적으로 92% 상승할 수 있다고 예측하고 있다. 이는 중국의 이 소매 기술 대기업이 실망스러운 2분기 실적에 이어 단 두 번의 세션 만에 주가가 35% 이상 폭락한 이후에 나온 것이다.

PDD 홀딩스, 이틀 만에 35% 하락했지만, 분석가들은 92%의 상승 가능성을 예측

Biogen Inc

Analysts' ratings for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Biogen, presenting an average target of $224.76, a high estimate of $300.00, and a low estimate of $138.00. A 15.18% drop is evident in the current average compared to the previous average price target of $265.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1735840816_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Biogen by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$138.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$164.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$178.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$180.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$207.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$255.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$204.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Biogen's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Biogen's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>All You Need to Know About Biogen</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Biogen: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Biogen's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -2.55% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biogen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.76% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.41%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.41%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.41, Biogen adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

17 Analysts Assess Biogen: What You Need To Know

Piper Sandler analyst Christopher Raymond downgrades Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Overweight to Neutral and lowers the price target from $315 to $138.

News

Downgrades

Price Target

Piper Sandler Downgrades Biogen to Neutral, Lowers Price Target to $138

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>BMO Capital analyst Evan Seigerman downgraded the rating for Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Outperform to Market Perform and lowered the price target from $230 to $164. Biogen shares closed at $147.39 on Thursday. <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group analyst Cristina Fernandez downgraded NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Outperform to Market Perform and slashed the price target from $93 to $80. Nike shares closed at $77.10 on Thursday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Thomas Stephan downgraded the rating for RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) from Buy to Hold and lowered the price target from $65 to $40. RxSight shares closed at $38.19 on Thursday. <a href="https://www.benzinga.com/quote/RXST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst Aidan Hall downgraded Lazard, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) from Outperform to Market Perform and cut the price target from $65 to $57. Lazard shares closed at $50.49 on Thursday. See how other analysts view this stock.</li>
<li>Citigroup analyst Thomas Palmer downgraded Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) from Buy to Neutral and lowered the price target from $90 to $68. Lamb Weston shares closed at $62.50 on Thursday. <a href="https://www.benzinga.com/quote/LW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NKE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="568" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095825/image-184-1024x568.png" alt="" class="wp-image-701967" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095825/image-184-1024x568.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095825/image-184-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095825/image-184-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095825/image-184.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Markets

RXST

This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

BMO Capital analyst Evan Seigerman downgrades Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Outperform to Market Perform and lowers the price target from $230 to $164.

BMO Capital Downgrades Biogen to Market Perform, Lowers Price Target to $164

Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is walking a tightrope this week, with its spot on the <a href="https://www.benzinga.com/topic/nasdaq-100">Nasdaq 100 Index</a> hanging in the balance. 
As the index reshuffles its lineup every December, the San Jose, California-based firm finds itself on the potential chopping block, alongside other underperforming stocks like Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Super Micro Computer benefitted from the surging demand for artificial intelligence infrastructure. At one point, it boasted a market cap of $67 billion. But a recent auditing scandal <a href="https://www.benzinga.com/24/12/42290180/cleared-of-fraud-but-super-micros-visibility-into-compliance-remains-low-says-analyst">caused its market cap to plummet</a>; it&#8217;s currently hovering at just below $20.4 billion.
Ernst &amp; Young flagged governance issues, sparking investor concerns, though a special committee later concluded these claims lacked sufficient evidence.
Super Micro Computer CEO Charles Liang expressed confidence at the Reuters NEXT conference, assuring investors that the company will meet its financial filing deadlines and remain on track for a February resolution.
Liang emphasized Super Micro&#8217;s robust relationships with major clients like xAI and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which could help stabilize its trajectory.
Read Also: <a href="https://www.benzinga.com/markets/24/12/42432508/smci-stock-drops-in-pre-market-despite-super-micro-ceos-assurance-against-delisting-whats-going-on">SMCI Stock Drops In Pre-Market Despite Super Micro CEO&#8217;s Assurance Against Delisting: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">Super Micro Computer Stock Chart Raises Questions</h2>
The technical charts, however, tell a mixed story. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="627" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11132847/Screenshot-2024-12-11-at-11.58.31-PM.png" alt="" class="wp-image-688046" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11132847/Screenshot-2024-12-11-at-11.58.31-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11132847/Screenshot-2024-12-11-at-11.58.31-PM-300x233.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121224&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Super Micro Computer stock, at $37.95, is trading below its eight-day simple moving average (SMA) of $41.47, signaling short-term selling pressure. Yet, its 20-day SMA of $33.38 and 50-day SMA of $37.10 suggest medium-term strength, offering a glimmer of hope.
Still, the long-term picture looks bleak with a 200-day SMA at $67.21—a stark reminder of the stock's fall from grace.
<h2 class="wp-block-heading">JPMorgan's Take</h2>
Despite market skepticism, JPMorgan sees stability in Super Micro's order book and customer base. The firm highlighted "robust" orders and no signs of significant customer churn. 
With Nvidia's Blackwell product line gearing up for a major ramp in late fiscal 2025, the company&#8217;s role in AI infrastructure could prove pivotal.
<h2 class="wp-block-heading">The Verdict</h2>
While Super Micro clings to the hope of staying on the Nasdaq 100, Friday&#8217;s decision will likely hinge on its market value relative to stronger contenders like Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) and MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>). The clock is ticking for SMCI to prove it still belongs among tech&#8217;s elite.
Stay tuned — Friday the 13th could mark a turning point for this embattled AI infrastructure pioneer.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42444582/albertsons-puts-an-end-to-merger-deal-sues-kroger-following-court-ruling-we-believe-strongly-in-the-merits-of-our-case">Albertsons Puts End To Merger Deal, Sues Kroger Following Court Ruling: &#8216;We Believe Strongly In The Merits Of Our Case&#8217;</a></li>
</ul>
Image: Shutterstock

Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory?

B of A Securities analyst Tim Anderson reinstates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral and announces $178 price target.

Initiation

B of A Securities Reinstates Neutral on Biogen, Announces $178 Price Target

Jefferies downgraded Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), citing the <a target="_blank" href="https://www.benzinga.com/24/11/42045417/biogens-outlook-dims-as-needham-projects-flat-revenue-until-2026" rel="noreferrer noopener">company&#8217;s tough setup</a>.
Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.
Challenges like PET scan reimbursement, slow protocol updates at major hospital networks, and identifying eligible patients continue to hinder adoption.
The analyst sees limited downside at current valuations and notes that continued pipeline progress, regulatory approvals, and a successful lecanemab launch could push the stock to around $350.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42096543/biogen-gains-momentum-with-positive-lupus-drug-results-analyst-sees-modest-valuation-upside" rel="noreferrer noopener">Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside</a>
Additionally, Jefferies writes that strategic options, particularly amid the CEO transition, provide a safety net if the stock drops to about $175.
Biogen acknowledges these obstacles vary by hospital or office, adding complexity to addressing them and setting clear timelines for resolution.
Meanwhile, Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) newly launched Kisunla (donanemab) is performing well, including some <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39620867/eli-lillys-alzheimers-therapys-broad-label-reflects-regulatory-confidence-in-anti-a" rel="noreferrer noopener">initial inventory stocking</a>.
Jefferies downgraded Biogen from Buy to Hold with a price target of $180, <a target="_blank" href="https://www.benzinga.com/quote/BIIB/analyst-ratings" rel="noreferrer noopener">down from $250</a>.
The analyst highlights a lack of exciting new developments to attract investor interest. Analysts noted that while Biogen has $7-10 billion in capacity for business deals, these efforts will take time to materialize.
Additionally, they highlighted a significant risk in 2030, when royalties from Ocrevus—currently worth $1.5 billion annually—are expected to drop by more than 50% due to the FDA approval of biosimilars. This reduction could cut Biogen's earnings per share by 20-30%.
Jefferies writes the company may seek to acquire &#8220;tuck-in&#8221; specialty commercial areas.
Biogen faced several pipeline setbacks in 2024, including programs for ALS, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39935226/sage-biogen-shelve-development-of-nervous-system-disorder-drug-after-data-disappoints" rel="noreferrer noopener">tremor</a>, and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38878003/tale-of-two-ionis-partnered-neurology-focused-early-stage-assets-biogen-discontinues-one-decides-" rel="noreferrer noopener">Angelman syndrome</a>.
Two promising late-stage programs, felzartamab entering Phase 3 trials for IgA nephropathy and dapi starting a second Phase 3 trial for lupus, show potential.
However, their results are years away (expected in 2027-2029), and both target highly competitive markets. As such, these drugs are unlikely to address concerns about Biogen&#8217;s earnings growth between 2025 and 2030.
Price Action: BIIB stock is up 0.18% at $158.06 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42394872/jack-ma-makes-rare-appearance-at-alibaba-fintech-event-stresses-on-ai-revolution" target="_blank" rel="noreferrer noopener">Jack Ma Makes Rare Appearance At Alibaba Fintech Event Stresses On AI Revolution</a></li>
</ul>

Analyst Color

Biotech

Equities

Health Care

General

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Betsy Graseck downgraded the rating for Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) from Overweight to Equal-Weight but raised the price target from $48 to $55. Bank of America shares closed at $46.75 on Friday. See how other analysts view this stock.</li>
<li>Leerink Partners analyst Puneet Souda downgraded Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Outperform to Market Perform and slashed the price target from $30 to $21. Myriad Genetics shares closed at $15.13 on Friday. <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Michael Yee downgraded the rating for Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Buy to Hold and lowered the price target from $250 to $180. Biogen shares closed at $157.78 on Friday. See how other analysts view this stock.</li>
<li>B of A Securities analyst Vivek Arya downgraded Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) from Buy to Neutral and lowered the price target from $180 to $155. AMD shares closed at $138.59 on Friday. <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Sandeep Deshpande downgraded the rating for STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Overweight to Neutral. STMicroelectronics shares closed at $26.43 on Friday. <a href="https://www.benzinga.com/quote/STM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="616" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-1024x616.png" alt="" class="wp-image-683191" style="width:572px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-1024x616.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-768x462.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

Pre-Market Outlook

MYGN

This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a high estimate of $300.00 and a low estimate of $180.00. Highlighting a 8.24% decrease, the current average has fallen from the previous average price target of $263.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733745644_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Biogen by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$180.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$207.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$255.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$204.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$269.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Biogen. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Biogen's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Biogen's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>Delving into Biogen's Background</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Biogen: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Biogen's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -2.55%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biogen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.76% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Biogen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.41% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Biogen's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.41% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.41.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Biogen: Insights From 19 Financial Analysts

Jefferies analyst Michael Yee downgrades Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Buy to Hold and lowers the price target from $250 to $180.

Jefferies Downgrades Biogen to Hold, Lowers Price Target to $180

GeneDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), Praxis Precision Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) and Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) as the founding partners to its Patient Access Program for pediatric epilepsy, which provides access to whole exome sequencing.
Currently, access to a definitive genetic diagnosis in pediatric epilepsy remains limited, as evidenced by the 5–8-year diagnostic odyssey that many children face.1 While patients may receive targeted multi-gene panel testing, there are more than 700 different genes related to seizures, and less than 50% of those genes are included on most commercially available gene panels.2 This program increases access to exome testing, increasing the chance of receiving a definitive diagnosis. Nearly 25% of patients with seizures received a genetic diagnosis through exome testing, compared to a previously reported 19% diagnostic yield for epilepsy gene panels.3

PRAX

STOK

GeneDx Announces Biogen, Praxis Precision Medicines And Stoke Therapeutics As The Founding Partners To Its Patient Access Program For Pediatric Epilepsy, Which Provides Access To Whole Exome Sequencing.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")), Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", Biogen", ) announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI&#xAE;" (lecanemab) for the treatment of early Alzheimer's disease (AD)&#x2A;.

Global

Biogen Announces LEQEMBI Approved For The Treatment Of Early Alzheimer's Disease In Mexico

Contracts

Biogen Exec Says Co Expects "A Linear Trend" Of Adding About $10M In U.S. Sales Per Quarter For Leqembi In The Near-Term

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$20.00</td>
<td>$127.4K</td>
<td>2.2K</td>
<td>5.0K</td>
</tr>
<tr>
<td>NMRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.50</td>
<td>$86.5K</td>
<td>4.5K</td>
<td>827</td>
</tr>
<tr>
<td>SRRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$40.00</td>
<td>$27.7K</td>
<td>3.2K</td>
<td>805</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$105.00</td>
<td>$28.5K</td>
<td>901</td>
<td>558</td>
</tr>
<tr>
<td>RVMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$55.00</td>
<td>$55.4K</td>
<td>704</td>
<td>461</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$285.00</td>
<td>$31.0K</td>
<td>1.1K</td>
<td>439</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$91.00</td>
<td>$49.3K</td>
<td>28</td>
<td>413</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$200.00</td>
<td>$108.0K</td>
<td>280</td>
<td>212</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.00</td>
<td>$109.2K</td>
<td>365</td>
<td>105</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.50</td>
<td>$25.3K</td>
<td>11.2K</td>
<td>66</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For ADMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), we notice a call option trade that happens to be bullish, expiring in 18 day(s) on December 20, 2024. This event was a transfer of 1499 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $127.4K, with a price of $85.0 per contract. There were 2293 open contracts at this strike prior to today, and today 5072 contract(s) were bought and sold. 
• For NMRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>), we notice a put option sweep that happens to be bullish, expiring in 46 day(s) on January 17, 2025. This event was a transfer of 309 contract(s) at a $7.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $86.5K, with a price of $280.0 per contract. There were 4550 open contracts at this strike prior to today, and today 827 contract(s) were bought and sold. 
• Regarding SRRK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), we observe a call option trade with bearish sentiment. It expires in 46 day(s) on January 17, 2025. Parties traded 99 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $27.7K, with a price of $280.0 per contract. There were 3264 open contracts at this strike prior to today, and today 805 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a put option sweep with bullish sentiment. It expires in 4 day(s) on December 6, 2024. Parties traded 250 contract(s) at a $105.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $28.5K, with a price of $114.0 per contract. There were 901 open contracts at this strike prior to today, and today 558 contract(s) were bought and sold. 
• For RVMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>), we notice a call option sweep that happens to be bearish, expiring in 18 day(s) on December 20, 2024. This event was a transfer of 426 contract(s) at a $55.00 strike. This particular call needed to be split into 45 different trades to become filled. The total cost received by the writing party (or parties) was $55.4K, with a price of $135.0 per contract. There were 704 open contracts at this strike prior to today, and today 461 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 18 day(s) on December 20, 2024. Parties traded 100 contract(s) at a $285.00 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $310.0 per contract. There were 1197 open contracts at this strike prior to today, and today 439 contract(s) were bought and sold. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a call option sweep that happens to be bullish, expiring in 11 day(s) on December 13, 2024. This event was a transfer of 411 contract(s) at a $91.00 strike. This particular call needed to be split into 48 different trades to become filled. The total cost received by the writing party (or parties) was $49.3K, with a price of $120.0 per contract. There were 28 open contracts at this strike prior to today, and today 413 contract(s) were bought and sold. 
• Regarding BIIB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), we observe a call option trade with bearish sentiment. It expires in 136 day(s) on April 17, 2025. Parties traded 200 contract(s) at a $200.00 strike. The total cost received by the writing party (or parties) was $108.0K, with a price of $540.0 per contract. There were 280 open contracts at this strike prior to today, and today 212 contract(s) were bought and sold. 
• Regarding SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we observe a put option trade with bearish sentiment. It expires in 200 day(s) on June 20, 2025. Parties traded 50 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $109.2K, with a price of $2185.0 per contract. There were 365 open contracts at this strike prior to today, and today 105 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 410 day(s) on January 16, 2026. Parties traded 54 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $470.0 per contract. There were 11285 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ADMA

AMGN

NMRA

RVMD

SAVA

SRRK

10 Health Care Stocks With Whale Alerts In Today's Session

ESAIY

Reported Wednesday, Eisai and Biogen Introduce LEQEMBI In South Korea To Combat Alzheimer's And Mild Cognitive Impairment

Financial giants have made a conspicuous bearish move on Biogen. Our analysis of options history for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) revealed 12 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $307,864, and 2 were calls, valued at $62,250.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $185.0 for Biogen during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Biogen options trades today is 215.75 with a total volume of 4,319.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Biogen's big money trades within a strike price range of $100.0 to $185.0 over the last 30 days.
<h3>Biogen Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732646821_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$28.4</td>
<td>$22.7</td>
<td>$27.2</td>
<td>$185.00</td>
<td>$35.3K</td>
<td align="right">443</td>
<td align="right">13</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.7</td>
<td>$15.6</td>
<td>$15.6</td>
<td>$160.00</td>
<td>$34.3K</td>
<td align="right">335</td>
<td align="right">99</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$15.6</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$160.00</td>
<td>$34.1K</td>
<td align="right">335</td>
<td align="right">422</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$11.5</td>
<td>$11.4</td>
<td>$11.5</td>
<td>$170.00</td>
<td>$33.3K</td>
<td align="right">83</td>
<td align="right">52</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.7</td>
<td>$15.0</td>
<td>$15.7</td>
<td>$160.00</td>
<td>$33.0K</td>
<td align="right">335</td>
<td align="right">231</td>
</tr>
</tbody>
</table>

<h3>About Biogen</h3>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Having examined the options trading patterns of Biogen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Biogen</h3>
<ul>
<li>Trading volume stands at 594,099, with BIIB's price up by 0.47%, positioned at $159.45.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for Biogen</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $229.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup has revised its rating downward to Neutral, adjusting the price target to $190. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $270. 
&#x2A; An analyst from JP Morgan has decided to maintain their Neutral rating on Biogen, which currently sits at a price target of $210. 
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on Biogen with a target price of $207. 
&#x2A; An analyst from Needham has revised its rating downward to Hold, adjusting the price target to $270. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biogen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Smart Money Is Betting Big In BIIB Options

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and lowers the price target from $251 to $207.

Mizuho Maintains Outperform on Biogen, Lowers Price Target to $207

Investors with a lot of money to spend have taken a bearish stance on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BIIB, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Biogen.
This isn't normal.
The overall sentiment of these big-money traders is split between 22% bullish and 66%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $198,898, and 4 are calls, for a total amount of $138,060.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $130.0 to $200.0 for Biogen over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Biogen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Biogen's substantial trades, within a strike price spectrum from $130.0 to $200.0 over the preceding 30 days.
<h3>Biogen Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732131069_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$2.35</td>
<td>$1.35</td>
<td>$2.0</td>
<td>$155.00</td>
<td>$60.0K</td>
<td>1.5K</td>
<td align="right">663</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$22.6</td>
<td>$18.3</td>
<td>$19.32</td>
<td>$150.00</td>
<td>$48.3K</td>
<td>0</td>
<td align="right">25</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$29.6</td>
<td>$21.7</td>
<td>$24.0</td>
<td>$180.00</td>
<td>$48.0K</td>
<td>111</td>
<td align="right">20</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$8.6</td>
<td>$7.8</td>
<td>$8.6</td>
<td>$175.00</td>
<td>$35.2K</td>
<td>19</td>
<td align="right">4</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$2.1</td>
<td>$1.55</td>
<td>$2.09</td>
<td>$155.00</td>
<td>$33.5K</td>
<td>1.5K</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Biogen</h3>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Following our analysis of the options activities associated with Biogen, we pivot to a closer look at the company's own performance.
<h3>Where Is Biogen Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 839,529, with BIIB's price down by -0.49%, positioned at $154.67.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 83 days.</li>
</ul>
<h3>Professional Analyst Ratings for Biogen</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $261.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $270. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Biogen with a target price of $255. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $270. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Biogen, which currently sits at a price target of $300. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Biogen, targeting a price of $210. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biogen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Biogen Unusual Options Activity For November 20

On Tuesday, UCB SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>) and&nbsp;Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42054524/dapirolizumab-pegol-phase-3-data-presented-at-the-american-college-of-rheumatology-shows-significa" rel="noreferrer noopener">systemic lupus erythematosus</a>.
The drug candidate demonstrated significant clinical improvement in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41000544/biogenucb-partnered-autoimmune-disease-candidate-hits-primary-goal-in-late-stage-study-sets-stage" rel="noreferrer noopener">Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial</a>
The results were shared at the American College of Rheumatology&#8217;s annual meeting. In the 321-subject trial, DZP was administered intravenously every four weeks.
On the primary endpoint measuring improvement of moderate-to-severe disease activity after 48 weeks, study participants receiving DZP plus standard care had a statistically significant 14.6% higher response rate (49.5%) than those receiving SOC alone (34.6%).
On the first secondary endpoint of disease activity response at Week 24, study participants receiving DZP plus SOC had a 7.9% higher response rate (46.6%) than those receiving SOC alone (38.3%). However, the difference did not reach statistical significance.
A greater response was observed across multiple clinical endpoints among participants treated with DZP, including 50% less severe disease flares than participants on standard of care alone.
Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study.
In 2024, UCB and Biogen will initiate a second Phase 3 trial of dapirolizumab pegol, PHOENYCS FLY.
From a stock perspective, William Blair writes that dapirolizumab isn&#8217;t significantly impacting Biogen&#8217;s valuation, as investors remain focused on Leqembi&#8217;s commercial rollout, which is still a work in progress.
The success of Biogen&#8217;s late-stage development programs is crucial for future growth, complementing opportunities from Leqembi, Skyclarys, and potentially zuranolone, especially as its multiple sclerosis business continues to feel pressure from generic competition.
Leqembi remains a growth driver, particularly with potential advancements like subcutaneous administration approval, though its progress has been slower than expected. Despite these challenges, Biogen&#8217;s modest valuation presents an upside, supported by its commercial portfolio and cost-cutting measures. The analyst maintains an <a target="_blank" href="https://www.benzinga.com/quote/biib/analyst-ratings" rel="noreferrer noopener">Outperform rating on the stock.</a>
Price Action: BIIB stock is down 0.72% at $154.31 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42092265/stmicroelectronics-targets-18-billion-revenue-eyes-22-24-margins-by-2028" target="_blank" rel="noreferrer noopener">STMicroelectronics Targets $20 Billion Revenue By 2030, Unveils 2027 Goals</a></li>
</ul>

Reiteration

UCBJF

UCBJY

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

<ul>
<li>Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activity</li>
<li>A greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care alone</li>
<li>Systemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ systems, primarily in women, for whom there is a significant need for additional treatment options</li>
</ul>

UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction

Beaten Down Biogen Stock Looks Attractive At Current Levels

How is SPY stock faring? The SPDR S&P 500 ETF Trust  is down 1.99% in the past 5 days but has risen about 26.8% year-to-date. According to TipRanks...

SPY ETF Update, 12/31/2024

GeneDx ($WGS) is among the best performing small cap stocks for 2024, posting over 2600% gain. The company analyzes the complete DNA of a person, a...

GeneDx (WGS), An Emerging Powerhouse in Genomics Sees Explosive Growth

Piper Sandler downgraded Biogen (BIIB) to Neutral from Overweight with a price target of $138, down from $315, following a transfer of coverage. Bi...

Biogen downgraded to Neutral from Overweight at Piper Sandler

How is VOO stock faring? The Vanguard S&P 500 ETF is down 0.15% in the past five days but has risen 25.78% over the past year.  According to TipRan...

VOO ETF News, 1/2/2025

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Alphabet, Uber downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Tesla (TSLA) reported below-cons...

Tesla reports below-consensus deliveries: Morning Buzz

Biogen cut to neutral at Piper Sandler on Alzheimer's headwinds

How is SPY stock faring? The SPDR S&P 500 ETF Trust  is down 0.41% in the past 5 days but has risen about 26.6% over the past year. According to Ti...

SPY ETF News, 1/3/2025

AAPL

ATUS

BABA

BITF

BPAQF

CACI

CALM

CRVS

CVNA

DECK

ESALF

FSLR

GOOG

GOOGL

INMB

KOPN

LAES

MODG

NISTF

NPSCY

NWFL

OBIO

REGN

SEZL

SOFI

SPHR

TSLA

UBER

XPON

YGMZ

Legal

Press Releases

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Piper Sandler

BMO Capital

B of A Securities

Jefferies

Mizuho

슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)는 이번 주 <a href="https://www.benzinga.com/topic/nasdaq-100">나스닥 100 지수</a>의 자리가 위태로운 상황에서 줄타기를 하고 있다.
매년 12월 이 지수가 라인업을 조정함에 따라 캘리포니아주 산호세에 본사를 둔 이 회사는 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) 및 바이오젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)과 같은 실적이 저조한 다른 주식들과 함께 잠재적인 제외 대상에 올라 있다.
슈퍼 마이크로 컴퓨터는 인공지능(AI) 인프라 수요 급증으로 수혜를 입었다. 한때 시가총액은 670억 달러에 이르렀다. 그러나 최근 감사 스캔들로 인해 <a href="https://www.benzinga.com/24/12/42290180/cleared-of-fraud-but-super-micros-visibility-into-compliance-remains-low-says-analyst" target="_blank" rel="noopener">시가총액이 급락</a>했다. 현재는 204억 달러 바로 아래에 머물고 있다.
언스트 &amp; 영(Ernst &amp; Young)이 거버넌스 문제를 제기하여 투자자들의 우려를 불러일으켰지만, 이후 특별 위원회는 이러한 주장에 충분한 증거가 없다고 결론지었다.
슈퍼 마이크로 컴퓨터의 CEO 찰스 리앙(Charles Liang)은 로이터 넥스트(NEXT) 회의에서 자신감을 표명하며, 회사가 재무 보고 기한을 준수하고 2월 해결을 위한 계획을 유지할 것이라고 투자자들에게 확신했다.
리앙은 슈퍼 마이크로가 xAI 및 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 같은 주요 고객들과 강력한 관계를 유지하고 있다는 점을 강조하여 회사의 경로를 안정화할 수 있을 것이라고 언급했다.
추가 읽기: <a href="https://www.benzinga.com/markets/24/12/42432508/smci-stock-drops-in-pre-market-despite-super-micro-ceos-assurance-against-delisting-whats-going-on">슈퍼 마이크로 CEO의 상장폐지 방지 보장에도 불구하고 SMCI 주가가 프리마켓에서 하락한 이유는?</a>
<h2 class="wp-block-heading">슈퍼 마이크로 컴퓨터 주식 차트에 대한 질문</h2>
그러나 기술적 차트는 엇갈린 이야기를 전한다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-688046" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11132847/Screenshot-2024-12-11-at-11.58.31-PM.png" sizes="(max-width: 627px) 100vw, 627px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11132847/Screenshot-2024-12-11-at-11.58.31-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11132847/Screenshot-2024-12-11-at-11.58.31-PM-300x233.png 300w" alt="" width="627" height="487" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121224&amp;t=be2bearmibe3na1">차트는 Benzinga Pro를 사용하여 생성되었습니다</a>
슈퍼 마이크로 컴퓨터 주식은 현재 37.95달러로 8일 단순 이동 평균(SMA)인 41.47달러 아래에서 거래되고 있어 단기 매도 압을 신호한다. 하지만 20일 SMA인 33.38달러와 50일 SMA인 37.10달러는 중기적인 강세를 시사하여 희망의 빛을 제공한다.
그럼에도 불구하고, 장기적인 전망은 암울하며 200일 SMA는 67.21달러로, 주식이 한때의 영광에서 추락했음을 상기시킨다.
<h2 class="wp-block-heading">JP모건의 의견</h2>
시장 회의론에도 불구하고, JP모건은 슈퍼 마이크로의 주문 장부와 고객 기반에서 안정성을 보고 있다. 이 회사는 &#8220;강력한&#8221; 주문과 중요한 고객 이탈 조짐이 없다고 강조했다.
엔비디아의 블랙웰(Blackwell) 제품 라인이 2025년 회계연도 말에 대규모 확장을 준비하고 있는 가운데, AI 인프라에서 이 회사의 역할이 중추적인 역할을 할 수 있다.
<h2 class="wp-block-heading">결론</h2>
슈퍼 마이크로 컴퓨터가 나스닥 100에 남기를 바라는 희망을 품고 있는 가운데, 금요일의 결정은 팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) 및 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)와 같은 더 강력한 경쟁자들에 대한 시장 가치에 따라 달라질 것이다. SMCI가 여전히 기술 분야의 엘리트들과 함께할 자격이 있음을 증명할 시간이 촉박해지고 있다.
13일 금요일은 이 어려운 상황에 처한 AI 인프라 선도 기업에 전환점이 될 수 있다.
주가 움직임: 슈퍼 마이크로 컴퓨터의 주식은 수요일 5.55% 하락한 38.29달러에 마감되었다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42444582/albertsons-puts-an-end-to-merger-deal-sues-kroger-following-court-ruling-we-believe-strongly-in-the-merits-of-our-case">앨버트슨스, 법원 판결 후 인수합병 협상 종료 및 크로거 고소: &#8216;우리 사건의 타당성을 강하게 믿고 있다&#8217;</a></li>
</ul>
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 상당한 상승 기회를 제시하고 있으며, 분석가들은 현재 수준에서 잠재적으로 92% 상승할 수 있다고 예측하고 있다. 이는 중국의 이 소매 기술 대기업이 <a href="https://www.benzinga.com/markets/asia/24/08/40561208/chinese-retail-giant-pdd-plummets-nearly-30-after-disappointing-earnings-which-etfs-are-most-impacte" target="_blank" rel="noopener">실망스러운 2분기 실적</a>에 이어 단 두 번의 세션 만에 주가가 35% 이상 폭락한 이후에 나온 것이다.
<h3>무슨 일이 발생했나요?</h3>
이전에 핀둬둬(Pinduoduo Inc.)로 알려졌던 PDD는 2분기 실적 발표 이후 월요일에 29%의 엄청난 하락을 겪었으며, 이는 2018년 IPO 이후 최악의 하루 하락세를 기록했다.
국내 경쟁 심화와 국제 시장 불확실성으로 인한 성장 둔화에 대한 이 회사의 지침은 투자자들을 불안하게 만들었다.
그러나 경영진은 가맹점 지원 강화와 공급망 효율성 향상을 포함하는 &#8216;고품질 성장&#8217;에 초점을 맞춘 전략을 강조했다.
또한 읽기: <a href="https://www.benzinga.com/news/24/08/40582085/whats-going-on-with-temu-parent-pdd-holdings-stock-after-earnings" target="_blank" rel="noopener">실적 발표 후 테무의 모회사 PDD 홀딩스의 주식은 어떻게 되나요?</a>
<h3>애널리스트 반응</h3>
PDD 홀딩스의 실망스러운 2분기 결과에 따라 몇몇 분석가들은 이 회사의 예측과 가격 목표를 수정했다. 최근 분석가의 조치를 요약하면 다음과 같다:
<ul>
<li>벤치마크(Benchmark)는 PDD Holdings의 목표 가격을 210달러에서 185달러로 낮추고 매수 등급을 유지했다. "우리는 증가된 위험 요소를 인식하지만 PDD의 기본은 깨지지 않았다고 믿고 있다"고 그들이 지적했다. 벤치마크는 업데이트된 추정치를 반영하기 위해 목표 가격을 185달러로 수정했으며, 주식이 12개월 수익 추정치의 10배 미만으로 거래되고 있음을 나타내어 매력적인 가치 평가를 제공했다.</li>
<li>골드만삭스는 목표주가를 184달러에서 165달러로 낮추었지만 PDD에 대해서는 매수 의견을 유지했다. 분석가 로널드 겅(Ronald Keung)은 시장이 PDD의 강화된 생태계와 보다 명확한 총 상품량(GMV) 성장 전망을 과소평가하고 있다고 지적했다. 그는 회사의 이전 공격적인 광고 수익화 전략이 억제되어 보다 지속 가능한 성장으로 이어질 수 있다고 강조했다.</li>
<li>씨티그룹은 중립 등급을 유지하면서 목표 주가를 138달러에서 110달러로 낮췄다. 은행은 예상보다 부진한 수익과 경쟁 심화를 등급 하향 요인으로 꼽았다.</li>
<li>노무라 인스티넷은 목표 주가를 116달러에서 105달러로 낮추었지만 중립 등급을 유지했다. 애널리스트 팀은 목표를 수정한 이유로 회사의 부진한 2분기 실적과 향후 매출 성장에 대한 우려를 지적했다.</li>
<li>맥쿼리(Macquarie)는 목표주가를 160달러에서 140달러로 낮추고 아웃퍼폼 등급을 유지했다. 감산에도 불구하고 맥쿼리는 시장이 단기적인 이슈에 과민반응하고 있다고 믿으며 여전히 주식에 대해 낙관적인 입장을 유지하고 있다.</li>
<li>바클리즈(Barclays)는 동일가중(Equal Weight) 등급을 유지하면서 목표 가격을 98달러에서 84달러로 낮췄다. 바클리즈는 국내 시장의 경쟁이 심화되는 가운데 PDD 성장의 지속 가능성에 대한 우려를 표명했다.</li>
</ul>
<h3>PDD에 대한 애널리스트의 최근 조치 요약</h3>
<figure class="wp-block-table is-style-stripes">
<table>
<thead>
<tr>
<th>회사</th>
<th>이전 목표 주가</th>
<th>새로운 목표 주가</th>
<th>평가</th>
</tr>
</thead>
<tbody>
<tr>
<td>벤치마크</td>
<td>$210</td>
<td>$185</td>
<td>매수</td>
</tr>
<tr>
<td>씨티그룹</td>
<td>$138</td>
<td>$110</td>
<td>중립</td>
</tr>
<tr>
<td>노무라 인스티넷</td>
<td>$116</td>
<td>$105</td>
<td>중립</td>
</tr>
<tr>
<td>맥쿼리</td>
<td>$160</td>
<td>$140</td>
<td>아웃퍼폼</td>
</tr>
<tr>
<td>바클리즈</td>
<td>$98</td>
<td>$84</td>
<td>중립</td>
</tr>
</tbody>
</table>
</figure>
<h3>30% 이상 상승 잠재력이 있는 상위 나스닥 100 종목</h3>
여기 월스트리트 애널리스트들이 상당한 상승 잠재력이 있다고 판단하는 다른 나스닥 100 종목들을 살펴보았습니다:
<figure class="wp-block-table is-style-stripes">
<table>
<thead>
<tr>
<th>이름</th>
<th>12개월 기준 애널리스트 목표 주가 대비 최근 주가</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDD 홀딩스</td>
<td>93.13%</td>
</tr>
<tr>
<td>마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)</td>
<td>61.45%</td>
</tr>
<tr>
<td>모더나 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>50.07%</td>
</tr>
<tr>
<td>슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>48.86%</td>
</tr>
<tr>
<td>바이오젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)</td>
<td>37.75%</td>
</tr>
<tr>
<td>달러 트리 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)</td>
<td>36.27%</td>
</tr>
<tr>
<td>덱스콤 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCOM#NASDAQ">DCOM</a>)</td>
<td>30.88%</td>
</tr>
</tbody>
</table>
</figure>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40584992/investors-funnel-2-2b-into-these-5-real-estate-etfs-in-anticipation-of-fed-rate-cuts">투자자들이 연준 금리 인하 예상에 따라 이 5개 부동산 ETF에 22억 달러를 쏟아부었다.</a></li>
</ul>
사진: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Biogen

뉴스

에 대한 최신 뉴스 Biogen (NASDAQ:BIIB) 주식

수요일, 12월 11, 2024

화요일, 8월 27, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌